# Arbutus Biopharma Corporation (ABUS)

**Exchange:** NASDAQ  
**Sector:** Healthcare  
**Market cap:** $789M  
**Price:** $4.12 (-3.06%)

> Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company specializing in virology with a focus on developing novel therapeutics for infectious diseases, particularly chronic hepatitis B virus (cHBV). The company leverages its deep expertise in virology to create innovative treatments that target HBV through multiple mechanisms of action, aiming to provide functional cures for patients with unmet medical needs. Its proprietary pipeline features imdusiran (AB-729), a subcutaneously delivered RNAi therapeutic that suppresses all HBV antigens including HBsAg, currently in phase 2a clinical trials, and AB-101, an oral PD-L1 inhibitor in phase 1a/1b trials designed to reawaken HBV-specific immune responses. Arbutus Biopharma Corporation also advances its in-house Lipid Nanoparticle (LNP) delivery technology to enhance therapeutic delivery. These efforts position the company as a key player in the biotechnology sector, contributing to improved treatment options in hepatology and viral disease management. Founded in 2005 and headquartered in Warminster, Pennsylvania, Arbutus Biopharma Corporation maintains a portfolio of clinical and pre-clinical assets dedicated to addressing critical virology challenges.

## Income Statement (Annual, USD)

| Fiscal Year | Revenue | Gross Profit | Operating Income | Net Income | EPS (dil.) |
| --- | --- | --- | --- | --- | --- |
| 2025 | $14M | — | -$38M | -$34M | — |
| 2024 | $6M | — | -$76M | -$70M | — |
| 2023 | $18M | — | -$78M | -$73M | — |
| 2022 | $39M | — | -$65M | -$69M | — |
| 2021 | $11M | — | -$74M | -$76M | — |
| 2020 | $7M | — | -$58M | -$64M | — |
| 2019 | $6M | — | -$144M | -$154M | — |
| 2018 | $6M | — | -$90M | -$57M | — |
| 2017 | $11M | — | -$111M | -$84M | — |
| 2016 | $1M | — | -$492M | -$384M | — |
| 2015 | $23M | — | -$104M | -$63M | — |
| 2014 | $15M | — | -$33M | -$39M | — |
| 2013 | $15M | — | -$12M | -$14M | — |
| 2012 | $14M | — | -$13M | $30M | — |
| 2011 | $17M | — | -$11M | -$10M | — |

## Balance Sheet (Annual, USD)

| Fiscal Year | Total Assets | Total Liabilities | Equity | Cash | Long-term Debt |
| --- | --- | --- | --- | --- | --- |
| 2025 | $95M | $18M | $77M | $18M | — |
| 2024 | $132M | $34M | $97M | $36M | — |
| 2023 | $144M | $38M | $106M | $26M | — |
| 2022 | $195M | $59M | $137M | $31M | — |
| 2021 | $204M | $35M | $169M | $109M | — |
| 2020 | $137M | $35M | $102M | $52M | — |
| 2019 | $106M | $33M | $73M | $32M | — |
| 2018 | $228M | $28M | $200M | $37M | — |
| 2017 | $237M | $55M | $182M | $54M | — |
| 2016 | $276M | $73M | $203M | $23M | — |
| 2015 | $712M | $165M | $548M | $167M | — |
| 2014 | $118M | $30M | $88M | $72M | — |
| 2013 | $72M | $13M | $59M | $69M | — |

## Cash Flow (Annual, USD)

| Fiscal Year | Operating Cash Flow | CapEx | Free Cash Flow |
| --- | --- | --- | --- |
| 2025 | -$40M | — | -$40M |
| 2024 | -$65M | $182,000 | -$65M |
| 2023 | -$86M | $1M | -$87M |
| 2022 | -$35M | $512,000 | -$36M |
| 2021 | -$68M | $809,000 | -$68M |
| 2020 | -$51M | $229,000 | -$52M |
| 2019 | -$71M | $589,000 | -$72M |
| 2018 | -$68M | $1M | -$69M |
| 2017 | -$49M | $7M | -$56M |
| 2016 | -$58M | $4M | -$62M |
| 2015 | -$56M | $2M | -$59M |
| 2014 | -$12M | $1M | -$13M |
| 2013 | -$7M | $725,000 | -$7M |
| 2012 | $33M | $15,000 | $33M |
| 2011 | -$8M | $60,378 | -$8M |

Source: [CompaniesByCap](https://companiesbycap.com/company/ABUS)